Alejandro Calvo, MD
Hematology & Oncology · Kettering, OHNPI 1457341760
Payments from drug & device makers
Across 397 payments — averaging $1323.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$174K
- AstraZeneca$114K
- Genentech USA, Inc.$59K
- Lilly USA, LLC$56K
- Mirati Therapeutics, Inc.$49K
- Merck$34K
- plus $39K from 30 others
What the payments were for
- Consulting fees$21,9875%
- Speaking & faculty fees$383,34483%
- Grants$3500%
- Travel & lodging$44,63310%
- Food & beverage$11,1702%
- Education$1,8770%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Jazz Pharmaceuticals Inc. | 107 | $173,735 |
| AstraZeneca(2 entities) | 83 | $114,441 |
| Genentech USA, Inc. | 40 | $59,423 |
| Lilly USA, LLC | 73 | $55,863 |
| Mirati Therapeutics, Inc. | 18 | $49,390 |
| Merck | 2 | $33,823 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $12,506 |
| Daiichi Sankyo Inc. | 8 | $10,056 |
| Johnson & Johnson | 6 | $2,860 |
| Astrazeneca UK Limited | 1 | $1,713 |
| G1 Therapeutics, Inc. | 1 | $1,500 |
| Janssen Scientific Affairs, LLC | 1 | $1,170 |
| Gilead | 2 | $1,012 |
| Athenex Pharmaceutical Division, LLC | 2 | $1,000 |
| Immunomedics, Inc. | 1 | $1,000 |
| E.r. Squibb & Sons, L.L.C. | 4 | $849 |
| Regeneron Healthcare Solutions, Inc. | 2 | $727 |
| Biontech SE | 7 | $619 |
| Boehringer Ingelheim | 1 | $520 |
| EMD Serono, Inc. | 1 | $500 |
| Beigene, Ltd. | 1 | $450 |
| Novartis | 2 | $246 |
| Tempus AI, Inc | 2 | $202 |
| Incyte Corporation | 2 | $198 |
| Beigene USA, Inc. | 2 | $187 |
| Dova Pharmaceuticals | 2 | $186 |
| Rigel Pharmaceuticals, Inc. | 2 | $180 |
| Pharmacyclics LLC, An Abbvie Company | 4 | $149 |
| Intuitive Surgical | 2 | $147 |
| CTI Biopharma Corp. | 1 | $139 |
| Pfizer | 2 | $136 |
| GSK | 1 | $123 |
| Sobi, Inc | 1 | $84 |
| Astellas Pharma US Inc | 1 | $82 |
| AbbVie | 2 | $60 |
| ADC Therapeutics America, Inc. | 1 | $30 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$525,306 in reported general payments places this provider in the 80th percentile of 450 hematology & oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 134 | $2,028,904 |
| Lenalidomide | 44 | $636,009 |
| VerzenioAbemaciclib | 41 | $630,765 |
| TagrissoOsimertinib Mesylate | 29 | $476,564 |
| PomalystPomalidomide | 20 | $404,823 |
| LenvimaLenvatinib Mesylate | 13 | $320,790 |
| BrukinsaZanubrutinib | 13 | $203,096 |
| EliquisApixaban | 178 | $172,732 |
| XtandiEnzalutamide | 12 | $169,284 |
| Everolimus | 13 | $158,875 |
| VenclextaVenetoclax | 18 | $144,650 |
| Abiraterone Acetate | 96 | $114,161 |
| XareltoRivaroxaban | 44 | $54,895 |
| Ondansetron Hcl | 113 | $12,410 |
| Anastrozole | 223 | $4,197 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCVerzenio, Olanzapine | $55,863 | $631,16969 claims |
| AstraZenecaTagrisso | $114,441 | $476,56429 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $849 | $404,82320 claims |
| Beigene USA, Inc.Brukinsa | $187 | $203,09613 claims |
| PfizerEliquis | $136 | $172,732178 claims |
| Astellas Pharma US IncXtandi | $82 | $169,28412 claims |
| AbbVieVenclexta | $60 | $144,65018 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $1,170 | $114,16196 claims |
| Johnson & JohnsonXarelto | $2,860 | $54,89544 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 450 hematology & oncology providers in Ohio.
Other hematology & oncology in Kettering
- Afshin DowlatiCleveland$25.1M
- Brian HillCleveland$11.6M
- Trisha Wise-DraperCincinnati$9.8M
- Davendra SohalCincinnati$8.6M
- Christopher HoimesCleveland$7.5M
- Balazs HalmosCleveland$7M
- David WaterhouseCincinnati$5.7M
- Dale ShepardCleveland$5.1M
- Paolo CaimiCleveland$4.2M
- Allison WinterCleveland$4.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.